peptidesinstitute.org
HORMONAL

Degarelix

Degarelix

GnRH Antagonist for Androgen Deprivation Therapy

Buy Degarelix
Based on the combined works of Dr. William A. Seeds and Dr. Ian W. Hamley
— authoritative voices whose published research informed this article

The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.

Overview

What is Degarelix?

Degarelix is a synthetic peptide GnRH (gonadotropin-releasing hormone) receptor antagonist approved for androgen deprivation therapy (ADT) in advanced prostate cancer. It consists of a modified decapeptide sequence that binds reversibly but with high affinity to pituitary GnRH receptors, immediately blocking the gonadotropin cascade that drives testicular testosterone synthesis. The result is a rapid, sustained reduction in serum LH, FSH, and testosterone without the initial hormonal surge that characterizes GnRH agonist therapy.

This absence of a testosterone flare distinguishes degarelix from GnRH agonists such as leuprolide. With agonist-based ADT, the initial receptor stimulation triggers a transient rise in testosterone (the 'flare') that can temporarily worsen bone pain, urinary obstruction, or spinal cord compression in men with metastatic disease. Because degarelix acts as a pure competitive antagonist from first dosing, testosterone suppression begins within days rather than weeks, and no flare occurs. In a pivotal Phase III trial of 610 patients, degarelix achieved testosterone levels at or below 0.5 ng/mL within three days in over 96% of subjects [1], compared to approximately three weeks required for leuprolide to reach castrate levels.

Degarelix was synthetically engineered to overcome the histamine-releasing properties that limited earlier GnRH antagonists such as abarelix. Its structural modifications result in very weak histamine-releasing activity, substantially reducing the risk of immediate hypersensitivity reactions that made earlier antagonists difficult to use in clinical practice. Upon subcutaneous administration, degarelix forms a gel-like depot at the injection site that releases the drug in a first-order manner, providing sustained pharmacological activity between monthly doses.

Beyond testosterone suppression, early data suggest that degarelix may offer cardiovascular advantages over GnRH agonists. Observational and retrospective analyses have found associations between degarelix use and lower rates of major adverse cardiovascular events compared to leuprolide [3], though prospective randomized data are still maturing. The PSA decline rate is also more rapid with degarelix, which may have prognostic relevance for monitoring treatment response.

Research Supply

Source high-purity Degarelix for your research

Buy Degarelix
Protocol

Dosage Guide

Route: Subcutaneous injection, abdominal region only; not available as oral formulation

Dosing Schedule

PeriodDose
Loading dose (Day 1)240 mg (two 120 mg subcutaneous injections)
Maintenance dose80 mg subcutaneous injection every 28 days

Reconstitution

VIAL SIZE120 mg (loading) or 80 mg (maintenance)
WATER VOLUME3 mL sterile water (120 mg vial); 4.2 mL sterile water (80 mg vial)
CONCENTRATION40 mg/mL (loading); 20 mg/mL (maintenance)
Both loading injections must be given on the same day in different abdominal areas

Injection Volumes

DoseVolumeSyringe Units
120 mg (x2 loading)3 mL per vialTwo separate injections, different sites
80 mg (maintenance)4 mLSingle monthly injection

Administration Tips

  • Administer only by subcutaneous injection in the abdominal region
  • Loading dose: both 120 mg injections must be given on Day 1 in different abdominal areas
  • Maintenance: one 80 mg injection every 28 days
  • Monitor serum testosterone prior to therapy and periodically during treatment
  • Confirm maintenance of castrate testosterone levels below 50 ng/dL (0.5 ng/mL)
  • Monitor PSA as a surrogate marker of disease response
Safety

Risks & Side Effects

Commonly Reported

Injection site reactions: pain, erythema, swelling, and induration (approximately 40% of patients; typically mild to moderate and transient)Hot flashes (flushing): the most common systemic effect, reported in 25-30% of patientsWeight gainFatigueChills (approximately 4% of patients)Elevated liver enzymes (transaminases): monitor LFTs periodically

Serious Risks

QT interval prolongation

Androgen deprivation in general is associated with QT prolongation. Use with caution in patients on QT-prolonging drugs or with baseline cardiac risk factors.

Bone mineral density loss

Chronic testosterone suppression leads to accelerated osteoporosis. Baseline and periodic bone density monitoring is recommended for patients on long-term ADT.

Metabolic effects

Insulin resistance, dyslipidemia, and increased cardiovascular risk are associated with long-term androgen deprivation therapy.

Depression and cognitive effects

Testosterone suppression can exacerbate depressive symptoms and may affect cognitive function. Monitor mental health during treatment.

Related Research

Related Peptides

Expert Voices

Experts Covering Degarelix

Dr. William A. Seeds

MD -- Regenerative Medicine Pioneer

Dr. Ian W. Hamley

Diamond Professor of Physical Chemistry -- University of Reading

LEGAL DISCLAIMER

The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Degarelix has not been approved by the FDA for any medical condition other than the treatment of advanced prostate cancer. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.

Frequently Asked Questions

What is Degarelix and how does it work?
Degarelix is a synthetic peptide GnRH receptor antagonist approved for androgen deprivation therapy in advanced prostate cancer. It immediately blocks pituitary GnRH receptors to suppress LH, FSH, and testosterone production. Unlike GnRH agonists, it achieves castrate testosterone levels within three days without any initial hormonal flare.
Why does Degarelix avoid the testosterone flare?
Degarelix is a pure competitive antagonist that blocks GnRH receptors from first dosing. GnRH agonists like leuprolide initially stimulate the receptor before desensitizing it, causing a temporary testosterone surge that can worsen cancer symptoms. Degarelix eliminates this dangerous 1 to 2 week flare period entirely.
How is Degarelix dosed?
The loading dose is 240 mg on Day 1, given as two separate 120 mg subcutaneous injections in different abdominal areas. Monthly maintenance is 80 mg subcutaneously every 28 days. Both injections form gel-like depots that release the drug in a sustained manner between doses.
What are Degarelix side effects?
Common effects include injection site reactions (approximately 40% of patients), hot flashes (25 to 30%), weight gain, fatigue, and elevated liver enzymes. Long-term androgen deprivation risks include bone density loss, insulin resistance, QT prolongation, depression, and cognitive effects from chronic testosterone suppression.
Does Degarelix have cardiovascular advantages over Lupron?
Early data suggest degarelix may offer cardiovascular advantages over GnRH agonists. Observational analyses found associations between degarelix use and lower rates of major adverse cardiovascular events [3] compared to leuprolide. Prospective randomized data are still maturing, but this potential benefit is clinically significant.
Is Degarelix used for anything besides prostate cancer?
Degarelix is FDA-approved only for advanced prostate cancer. Research has explored its use in other hormone-sensitive conditions, but these applications remain investigational. Its rapid, flare-free testosterone suppression makes it uniquely valuable when avoiding initial hormone surges is medically critical.

References

  1. Klotz L, Boccon-Gibod L, Shore ND, et al.. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008. PMID 19035858
  2. Van Poppel H, Nilsson S. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res. 2010. PMID 21188095
  3. Smith MR, Klotz L, Persson BE, et al.. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010. PMID 20952020

Regulatory & Official Sources